<div><p>The current interest in epigenetic priming is underpinned by the belief that remodelling of the epigenetic landscape will sensitise tumours to subsequent therapy. In this pre-clinical study, paediatric AML cells expanded in culture and primary AML xenografts were treated with decitabine, a DNA demethylating agent, and cytarabine, a frontline cytotoxic agent used in the treatment of AML, either alone or in combination. Sequential treatment with decitabine and cytarabine was found to be more effective in reducing tumour burden than treatment with cytarabine alone suggesting that the sequential delivery of these agents may a have real clinical advantage in the treatment of paediatric AML. However we found no evidence to suggest that th...
Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have ...
Decitabine may open the chromatin structure of leukemia cells making them accessible to the calichea...
Background. Acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet c...
The current interest in epigenetic priming is underpinned by the belief that remodelling of the epig...
Abstract Background Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltrans...
Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML) remain dismal. ...
Abstract Background Promotor hypermethylation of CpG islands is common in B cell precursor acute lym...
Epigenetic changes play an important role in the development of acute myeloid leukemia (AML). Unlike...
Decitabine (5-aza-2′-deoxycytidine) is a hypomethylating agent used in the treatment of acute myeloi...
Hypomethylating agents (HMA) have become the backbone of nonintensive acute myeloid leukemia/myelody...
Suppression of apoptosis by TP53 mutation contributes to resistance of acute myeloid leukemia (AML) ...
Because cladribine can increase cytarabine triphosphate levels, we tested a cladribine—cytarabine co...
ObjectiveTo explore the role of chidamide, decitabine plus priming regimen in the salvage treatment ...
Duncan, Randall L.Barwe, SonaliPediatric acute myeloid leukemia (AML) is a type of blood cancer, acc...
Background. Currently, overall survival rate for pediatric patients with acute myeloid leukemia (AML...
Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have ...
Decitabine may open the chromatin structure of leukemia cells making them accessible to the calichea...
Background. Acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet c...
The current interest in epigenetic priming is underpinned by the belief that remodelling of the epig...
Abstract Background Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltrans...
Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML) remain dismal. ...
Abstract Background Promotor hypermethylation of CpG islands is common in B cell precursor acute lym...
Epigenetic changes play an important role in the development of acute myeloid leukemia (AML). Unlike...
Decitabine (5-aza-2′-deoxycytidine) is a hypomethylating agent used in the treatment of acute myeloi...
Hypomethylating agents (HMA) have become the backbone of nonintensive acute myeloid leukemia/myelody...
Suppression of apoptosis by TP53 mutation contributes to resistance of acute myeloid leukemia (AML) ...
Because cladribine can increase cytarabine triphosphate levels, we tested a cladribine—cytarabine co...
ObjectiveTo explore the role of chidamide, decitabine plus priming regimen in the salvage treatment ...
Duncan, Randall L.Barwe, SonaliPediatric acute myeloid leukemia (AML) is a type of blood cancer, acc...
Background. Currently, overall survival rate for pediatric patients with acute myeloid leukemia (AML...
Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have ...
Decitabine may open the chromatin structure of leukemia cells making them accessible to the calichea...
Background. Acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet c...